Lung cancer screening rates mainly unchanged during pandemic

Lung cancer screening rates mainly unchanged during pandemic

(HealthDay)—Lung cancer screening (LCS) rates remained stable between 2019 and 2020 in the United States and increased in 19 states, according to a research letter published online July 19 in CHEST.

Stacey A. Fedewa, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined annual LCS rates before and during the pandemic nationally and by state. The numbers of LCS performed in 2019 and 2020 were obtained from the American College of Radiology Lung Cancer Screening public reports; LCS rates among eligible adults were compared before and during the pandemic.

The researchers found that 564,164 and 557,795 of the 8.51 million eligible adults received LCS in 2019 and 2020, respectively. The national LCS rates were unchanged between 2019 and 2020 (6.6 versus 6.5 percent; screening rate ratio [SRR], 0.99; 95 percent confidence interval, 0.97 to 1.01). In five states (Utah, Rhode Island, Vermont, Hawaii, and Maryland), SRRs declined statistically significantly by 23 to 52 percent between 2019 and 2020. SRRs were unchanged in 25 states and increased significantly in 19 states, including by ≥20 percent in Nevada, West Virginia, Maine, and Kentucky, during the same period.

"Although national LCS rates remained low and unchanged, 19 states experienced significant improvements despite the pandemic," the authors write. "Best practices from successful state and local LCS programs could inform ongoing efforts to detect lung cancers early."


Explore further

First population-based study finds state-level lung cancer screening rates not aligned with lung cancer burden in US

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Chest

Copyright © 2021 HealthDay. All rights reserved.

Citation: Lung cancer screening rates mainly unchanged during pandemic (2021, August 11) retrieved 28 May 2022 from https://medicalxpress.com/news/2021-08-lung-cancer-screening-unchanged-pandemic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors